People Science

High-Level Overview

People Science is a technology-enabled clinical research company headquartered in Los Angeles, California, founded in 2019. It provides a scaled R&D platform for alternative medicines, including a proprietary app called CHLOE (Consumer Health Learning and Organizing Ecosystem), which collects real-world health data from consumers via surveys, photos, wearables, and biological specimens to support affordable clinical trials for wellness, nutrition, and consumer health brands.[1][2][4][6] The company serves patients, consumers, providers, scientists, and health brands in sectors like psychedelics, cannabis, probiotics, plant-based medicines, nutraceuticals, and digital therapies, solving the problem of slow, costly, and disconnected clinical research by democratizing access to data-driven evidence for better health outcomes.[1][2][4] With $5.3M raised from investors like FORM Life Ventures, Noetic Fund, Acre Venture Partners, and Thia Ventures, it has shown growth through rapid participant recruitment, trial execution, and partnerships, such as with Verb Biotics for anxiety and sleep studies.[1][2][4]

Origin Story

People Science was co-founded in 2019 by Belinda Tan, MD, PhD (Co-CEO) and Noah Zimmerman, scientists and physicians united by a vision for participatory, transparent health research.[1][6] Belinda, born in Malaysia and raised in the U.S., previously served as co-founder and Chief Medical Officer at Science 37, a global clinical research tech firm, and as an Assistant Professor at Harbor-UCLA.[6] Their idea emerged from frustration with traditional clinical research's inaccessibility, aiming to study complex natural medicines and supplements in real-world settings via CHLOE.[4][6] Early traction came from building this platform to connect health brands, scientists, and consumers, securing $5.3M in funding, and delivering successful trials like Verb Biotics' under-budget study with rapid recruitment and manuscript preparation.[1][2][4]

Core Differentiators

• Affordable, Real-World Clinical Trials: Offers decentralized trials with flexible designs (e.g., randomized placebo-controlled, observational, longitudinal studies) at lower costs, using CHLOE for high-engagement data collection from photos, wearables, and specimens.[4]
• Proprietary CHLOE Platform: Consumer app for personalized health insights, participant coordination, and longitudinal data to identify super-users and bolster product claims.[1][2][4]
• End-to-End Services: Includes protocol design, principal investigators, IRB management, data analysis, manuscript preparation, and logistics, supplemented by a expert team like COO Ashley Mateus, PhD, and others in operations, research, and engineering.[4][6]
• Rapid Execution and Scalability: Proven in testimonials for under-budget recruitment, efficiency, and business-impacting insights, focusing on wellness sectors underserved by traditional research.[4]

(Note: A separate entity at people-science.com focuses on talent acquisition RPO with Hiregate tech, but query context aligns with peoplescience.health's health tech profile.[3][5])

Role in the Broader Tech Landscape

People Science rides the wellness and alternative medicine boom, where consumer demand for evidence-based products in psychedelics, cannabis, and nutraceuticals outpaces traditional science, amid regulatory shifts toward real-world evidence.[1][2][4] Timing is ideal as health tech evolves post-pandemic, with wearables and DTC data enabling faster, cheaper trials versus pharma's high-cost model, addressing market forces like consumer skepticism and innovators' need for trust-building proof.[4] It influences the ecosystem by empowering brands (e.g., nutrition firms) with clinical-grade data, fostering participatory research that bridges consumers, scientists, and providers for holistic health advancements.[1][6]

Quick Take & Future Outlook

People Science is positioned to scale as wellness evidence demands grow, potentially expanding CHLOE integrations with more wearables/AI for predictive health insights and entering adjacent markets like digital therapeutics.[1][4] Trends like decentralized trials, regulatory nods to real-world data, and investor interest in longevity/psychedelics (e.g., Noetic Fund) will propel it, evolving its role from trial enabler to central hub for alternative medicine R&D.[1][2] With a strong founding team and proven momentum, expect deeper brand partnerships and larger datasets driving industry standards—reinforcing its mission to make science accessible for collective health gains.[6]